Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Robinson Vidva"'
Autor:
Panagiotis Kratimenos, Abhya Vij, Robinson Vidva, Ioannis Koutroulis, Maria Delivoria-Papadopoulos, Vittorio Gallo, Aaron Sathyanesan
Publikováno v:
Journal of Neurodevelopmental Disorders, Vol 14, Iss 1, Pp 1-16 (2022)
Abstract Background Neonatal hypoxic brain injury is a major cause of intellectual and developmental disability. Hypoxia causes neuronal dysfunction and death in the developing cerebral cortex due to excitotoxic Ca2+-influx. In the translational pigl
Externí odkaz:
https://doaj.org/article/bfbd70b4100442eca832757bd4e54d0b
Autor:
Panagiotis Kratimenos, Abhya Vij, Robinson Vidva, Ioannis Koutroulis, Maria Delivoria-Papadopoulos, Vittorio Gallo, Aaron Sathyanesan
Publikováno v:
Journal of neurodevelopmental disorders. 14(1)
Background Neonatal hypoxic brain injury is a major cause of intellectual and developmental disability. Hypoxia causes neuronal dysfunction and death in the developing cerebral cortex due to excitotoxic Ca2+-influx. In the translational piglet model
Autor:
Ansu Kumar, Shireen Vali, Erliang Zeng, Kim A. Brogden, Carol L. Fischer, Amber M. Bates, Neeraj Kumar Singh, Taher Abbasi, Robinson Vidva, Xian Jin Xie, Georgia K. Johnson, Janet M. Guthmiller, Emily A. Lanzel
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Individual computational models of single myeloid, lymphoid, epithelial, and cancer cells were created and combined into multi-cell computational models and used to predict the collective chemokine, cytokine, and cellular biomarker profiles often see
Autor:
Anjanasree V. Lakshminarayana, Brian J. Druker, Shannon K. McWeeney, Christopher R. Cogle, Leylah Drusbosky, Stephen E. Kurtz, Shireen Vali, Vijayashree P Shyamasundar, Ashish Kumar Agrawal, Saji Gera, Taher Abbasi, Robinson Vidva, Cristina E. Tognon, Anay Talawdekar, Jeffrey W. Tyner
Publikováno v:
Leukemia research
Despite advances in understanding the molecular pathogenesis of acute myeloid leukaemia (AML), overall survival rates remain low. The ability to predict treatment response based on individual cancer genomics using computational modeling will aid in t
Autor:
Robinson Vidva, Neeraj Kumar Singh, Taher Abbasi, Anay Talawdekar, Rahul K Raman, Terzah M. Horton, Christopher R. Cogle, Mohammed Sauban, Fieke W Hoff, Steven M. Kornblau, Shireen Vali, Anuj Tyagi, Arko Das
Publikováno v:
Blood. 132:4034-4034
Background: Pediatric AML (pAML) treatment outcomes can vary due to genomic heterogeneity. Thus, selecting the right drugs for a given patient is challenging. There is a need for a priori means of predicting treatment responses based on tumor "omics"
Autor:
Leylah Drusbosky, Stephen E. Kurtz, Padmagiri G Chickdipatti, Christopher R. Cogle, Diwyanshu Sahu, Cristina E. Tognon, Robinson Vidva, R. Gopi, Rajeev Kumar, Taher Abbasi, Shweta Kapoor, Nithya T Raveendaran, Jeffrey W. Tyner, Shireen Vali, Brian J. Druker, Humera Azam
Publikováno v:
Blood. 132:1541-1541
Background: New prognostic factors have been recently identified in AML patient population that include frequent mutations of receptor tyrosine kinases (RTK) including KIT, PDGFR, FLT3, that are associated with higher risk of relapse. Thus, targeting
Autor:
Derek S. Borgwardt, Carol L. Fischer, Ann Progulske-Fox, Jianyi Yang, Prashant Ramachandran Nair, Yang Zhang, Shireen Vali, Robinson Vidva, Shwetha Chandrashekaraiah, Aaron D. Martin, Erica N. Recker, David R. Drake, Kim A. Brogden, Joseph E. Cavanaugh, Jonathan R. Van Hemert
Publikováno v:
Scientific Reports
Histatins are human salivary gland peptides with anti-microbial and anti-inflammatory activities. In this study, we hypothesized that histatin 5 binds to Porphyromonas gingivalis hemagglutinin B (HagB) and attenuates HagB-induced chemokine responses
Autor:
Taher Abbasi, Robinson Vidva, Shahabuddin Usmani, Pierrette Lo, Leylah Drusbosky, Neeraj Kumar Singh, Cristina E. Tognon, Christopher R. Cogle, Brian J. Druker, S. Radhakrishnan, Deepak Parashar, Shireen Vali, Jeffrey W. Tyner
Publikováno v:
Blood. 128:1713-1713
Background: Data from a small clinical trial of venetoclax in acute myeloid leukemia (AML) recently supported FDA breakthrough therapy designation for use in combination with hypomethylating agents in treatment-naïve patients who are ineligible for
Autor:
Karl G. Kohlgraf, Joseph E. Cavanaugh, Monica Raina, Lauren E. Harvey, Shireen Vali, Kim A. Brogden, Samiksha Avinash Prasad, S. Radhakrishnan, Ann Progulske-Fox, Leslie A. Mehalick, Erica N. Recker, Robinson Vidva
Publikováno v:
Scientific Reports
Human β defensin DEFB103 acts as both a stimulant and an attenuator of chemokine and cytokine responses: a dichotomy that is not entirely understood. Our predicted results using an in silico simulation model of dendritic cells and our observed resul